This 140 -year -old US pharmaceutical company will invest against Trump against Trump in India, and the first unit will be erected in this city.

US President Donald Trump’s pharmaceutical sector has begun to show the effect of 100% “tariff bomb”. US businesses leave the country and go abroad, which can benefit India directly. In fact, Elli Lily, one of the largest pharmaceutical businesses in the US, announced on Monday that it is investing $ 1 billion (about Rs 8,800 crore) in India. This investment will be made for new manufacturing units and quality functions over the next few years. This move from the company came at a time when Trump was preparing to demolish tariff bombs (Trump tariff on Pharma India) on the drug field. In such a situation, Eli Lily’s arrival in India could be a big boost for the ‘make in India’ campaign. What medicine produces the business, including cancer medicine? According to Elli Lily, this investment will strengthen the production of contracts and help patients around the world to produce medicines of diabetes, Alzheimer’s, cancer and auto -immune diseases. This investment is considered an important step towards establishing a new global identity of India’s healthcare sector. The 140 -year -old company employs 47,000 people. Elli Lily is one of the largest businesses in the United States and is one of the five largest businesses. The market cap is over $ 795 billion or about Rs 70 Lakh Crore. The 140 -year -old company has offices in 18 countries and offers medicine to approximately 125 countries. The company employs about 47,000 employees. The company is influenced by the Indian talent and strong infrastructure, Eli Lily said her decision to invest in India reflects the country’s competent talent, strong infrastructure and the government’s business -friendly policy. The company wants to make India an important center of its global health care network. Invest India CEO Nivriti Rai said: “The investment of Ellie Lily reflects India’s capacity and their confidence in policy stability. It will not only strengthen healthcare, but it will also speed up manufacturing in the country.” The pharmaceutical enterprise will set up a manufacturing unit in Hyderabad. The company said it would set up a new center for manufacturing and quality in Hyderabad. This center will oversee the contract construction network of Eli Lily across India and offer advanced technical facilities. Telangana’s chief minister Revevanth Reddy said: “Eli Lily shows that Hyderabad has become the center of global innovation in healthcare. The company recently launched an innovation center here, and now the new manufacturing center is coming.” The company said it would immediately start recruiting in positions such as engineers, chemists, analytical scientists, quality control and management. Patrick Johnson, president of Elli Lily International, said: “This investment will make India an important part of our world network. We are confident that India will become a new Health Care Building Center.” Increased investment by US businesses in India amid Trump’s policy clearly indicates that the world now sees India as a ‘Pharma Hub’.